The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESTRO 2025 | STAR-TREC: evaluating organ preservation in patients with early intermediate rectal cancer
Maria Antonietta Gambacorta, MD, Catholic University of the Sacred Heart, Milan, Italy, comments on the results of the STAR-TREC trial (NCT02945566), a Phase II/III randomized trial on patients with early intermediate rectal cancer. Prof. Gambacorta highlights that the trial found that long-course chemoradiation resulted in a higher rate of organ preservation (80%) compared to short-course radiotherapy (61%) at one year, suggesting that long-course chemoradiation is the preferred treatment for achieving organ preservation in these patients. This interview took place at the ESTRO 2025 congress in Vienna, Austria.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
